330 (PB318): Rational design of a superior single agent active, potential best-in-class WEE1/PKMYT1 inhibitor using Acrivon Predictive Precision Proteomics (AP3)
Baddour-Sousounis, J., Pasetto, M., Nilsson, H., Mitsa, G., Shi, L., Lombardo, P., Best, Z., Improgo, R., Kumar, S., Rappard, K., Hay, E., Muralitharan, U., Murshid, A., Shipitsin, M., Wigerup, C., Jakobsson, M.E., Jung, J., Proia, D.A., Masson, K., Blume-Jensen, P.
Published in European journal of cancer (1990) (01.10.2024)
Published in European journal of cancer (1990) (01.10.2024)
Get full text
Journal Article